How do blood banks know when a patient should get irradiated blood, if the patient's doctor forgets to order the blood to be irradiated?
A blood bank Technical Supervisor from a Midwest University Hospital is very familiar with the medical indications for the use of irradiated blood products and related issues, such as those discussed previously by the e-Network Forum at the following links:
He asks the following questions:
- How do blood banks know when a patient should get irradiated blood, if the patient's doctor forgets to order the blood to be irradiated?
- Do any colleagues employ an alert system, similar to that used by nursing services to alert caregivers when a patient has a risk of severe allergic reaction to penicillin, aspirin or other drugs?
- Has anyone had experience using Medic Alert bracelets to indicate that a patient has a special transfusion need, such as a need for irradiated products?
ADDENDA Feb. 28, 2005
The following comments have been received.
- A medical technologist in Iowa reports that their Meditech system alerts the technologist when an irradiated blood 'marker' had been applied to the patient's history record. If the current order does not include irradiation, it prompts the technologist to contact the doctor. In her opinion, this approach affords proper use of their resources in updating the patient's history.
- A former blood bank supervisor turned web designer would like to inquire of the MT in Iowa how the blood bank staff knows to place the "marker" in the patient's history to begin with (other than just relying on the physician order). She would like to know more about how a patient's diagnosis and indication might flag the original blood order. Once the blood bank knows the indication, it is easy to put a comment/marker/warning (whatever it is called in one's particular software package) into the computer database. In her opinion, the tricky part is how to make the blood bank aware of the indication for a patient's special transfusion requirements.
- A transfusion medicine physician and quality manager in Spain reports that GVHD is an increasing concern, as seen by the SHOT report, in which patients with B-cell malignancies were listed as being at increased risk of GVHD. Other reports have identified treatment with purine analogues as an independent risk factor for this problem. He feels that we need a proactive prevention strategy, taking into account the fact that B-cell lymphomas are increasing in frequency and fludarabine is being used for maladies other than lymphomas (i.e. autoimmune disorders).
He adds, "If a patient needs irradiated blood, it is easy to flag his/her transfusion record as such and this way the patient will always get this kind of blood until deemed unnecessary. Universal leukoreduction cannot be relied upon to prevent GVHD. The real problem is how to manage patients who will or may need irradiation but do not have a transfusion record in the blood bank. This implies the following:
- Previously you have decided which patients need irradiation of cellular products.
- There is a good communication between the blood bank and those clinical/laboratory areas which identify patients needing irradiation.
Some hospitals in Spain have developed the following strategies:
- The hospital pharmacy periodically sends the list of new patients receiving fludarabine and purine analogues to the blood bank, so that a transfusion record is opened for those patients and the need of irradiation stated, in case they need transfusion in the future, even if the patient has never been transfused.
- The Pathology Dept sends the blood bank a monthly list of new patients with B-cell malignancies, so that the transfusion record is opened. These data can be crossed with data from the pharmacy, not to duplicate records.
- These strategies are being applied to an increasing array of conditions such as AIDS, severe systemic lupus, other malignancies."
- A transfusion service supervisor in Northern California acknowledges that they have a similar concern about knowing when to use irradiated blood products. Presently, they rely on the nursing staff to contact them with the information on newly diagnosed patients (or new to their facility). They have indeed had a few close calls where a 'random' unit had been issued to the ward but caught before transfusion by a vigilant RN who realized that she hadn't given Transfusion Services the appropriate information. They are in the process of converting to an Electronic Medical Records system where the physician will be required to complete certain on-screen fields before ordering the crossmatch (or a product). The physician will be blocked from proceeding until answering yes or no to the need for irradiated and CMV negative components. Once a 'yes' is entered, that information will be interfaced with the LIS computer system, so the need for irradiation will go directly into the patient history. Hopefully this will avoid any additional near misses.
- A blood bank supervisor in Colorado reports that the first time a patient has an order for leukoreduced or irradiated products they add a "marker" to the patient's history file. It is usually other attending physicians that don't realize the patient has special needs. If irradiated products are not ordered, the transfusion service staff calls the nursing unit to have them check it out. Sometimes the physician feels that the patient no longer requires irradiated products. When this happens they remove the marker from the history file with a comment noting which doctor made the request. They are currently using the Meditech information system.
- A transfusion medicine physician who directs a busy service in Los Angeles reports that patients undergoing chemotherapy or radiation therapy at her hospital are assigned to the hematology/oncology unit, and orders originating from that location are flagged. In addition, transfusion medicine consultations, chart reviews, or surgical pathology reports may result in recommendations for a patient to receive irradiated blood products. Orders for irradiated blood are coded as a special transfusion need in the computer record (MISYS) which then flags that need for subsequent blood transfusions.
ADDENDA Mar. 1, 2005
- The blood bank Technical Supervisor from Iowa (#1 above) replies to the former blood bank supervisor (#2 above) that when he commented on the the issue the first time, he had read the question as relating to perpetuating irradiated blood after an initial order of it. His lab has no formal method of questioning a physician's blood order as it relates to irradiation. However he points out that if they suspect that it is needed, they would contact the physician or nurse for clarification. Clues that would prompt such contacts include :
- the patient's diagnosis
- the name of one of the physicians on the order or prior orders
- white blood cell or absolute neutrophil count. or other lab data
The responding colleague has struggled with this problem for decades. He laments that perhaps the blood banking community can finally bring pressure to implement some of the suggestions of some of the other e-Network Forum contributors.
ADDENDA Mar. 7, 2005
- A colleague in Florida, in reference to item #3 above, asks if there is a consensus on how long irradiated blood products should be continued following treatment with nucleotide analogs (such as Fludarabine). From his reading it looks like it should be at least 12-18 months, but some may advocate lifetime. His institution is in the process of writing a rule to alert physicians using Physician Order Entry of the need to order irradiated cellular components for these patients, and the need to build this into their decision alert.
ADDENDA Mar. 8, 2005
- The Medical Director of a Pediatric Transfusion Medicine service in a Boston hospital reports that they do not believe there is any sure way to ensure that a blood bank is always aware of a patient's need for irradiated blood. Hence, they irradiate ALL red cell, platelet, and whole blood units, except for emergency situations when there is no irradiated blood in inventory. They irradiate the blood products at the time of crossmatch if there is not an irradiated unit in inventory already. In his experience, the main difficulty with this approach at a pediatric hospital is that irradiation hastens release of potassium from red blood cells and infants receiving massive transfusions may suffer from hyperkalemia. This is especially challenging if there is a high crossmatch:transfusion ratio, since that can result in a relatively large inventory of irradiated units in the blood bank. He acknowledges that in effect, they have traded one challenge for another.
- A transfusion Medicine Specialist in a teaching hospital in New Zealand reports that her experience is that blood order requests do NOT always indicate that a patient should receive irradiated blood components when they need them. Because of this they seek information from as many sources as possible, to minimize the risk that a patient who needs irradiated blood fails to receive it.
- They highlight the requirement for irradiated blood in an electronic patient management system as soon as it is realized that the patient needs irradiated products. This alert also appears in the blood bank management system.
- They regularly acquire lists of the patients who are receiving purine analogs from the pharmacy and enter that information on the blood bank management system
- They maintain a 100% irradiated red cell and platelet inventory for pediatric/neonatal patients. They also irradiate all platelets that are supplied to hematology/oncology patients.
In spite of all the above measures some patients have slipped through the net. She asks rhetorically "Is there really any foolproof system?"
ADDENDA Apr. 17, 2006
- A medical technologist reports that her hospital transfusion service recently received an order for two units of irradiated, leukocyte reduced RBCs for transfusion of a group O, Rh positive pregnant sickle cell disease patient who was suffering a sickle cell 'crisis' at 23 weeks gestation. The physician did not request that the RBC donors be CMV seronegative or that the phenotype of the donor RBCs be matched with the C, E and K-antigen phenotype of the patient. The patient had a negative screen for unexpected red cell antibodies. The technologist contacted the local blood supplier and requested two units of group O, Rh positive, leukocyte reduced, irradiated RBCs, as requested by the physician. However, she also requested (in accordance with their local transfusion service policy) that the RBCs be CMV seronegative (because the patient was pregnant), and that the red cells be Hgb S negative and C-, E-, K-antigen negative because the patient has sickle cell disease. The inquiring medical technologist is uncertain why the donor red cell units had to be irradiated, but did comply with the physician's order. She is aware that intrauterine transfusions must be irradiated to prevent Graft versus Host Disease (GVHD) of the fetus/newborn, but she was not aware of random donor RBCs causing GVHD in pregnant women. She 'assumes' that the physician ordered the RBCs to be irradiated because pregnancy imposes some degree of immunosuppression so as to not reject the fetus, and because at her hospital the fetus would be transfused with leukocyte reduced, CMV seronegative, irradiated RBCs if it needed a transfusion shortly after birth. She wonders if there are clear guidelines or documentation that supports giving irradiated RBCs to a pregnant woman? If so, might the new mom's "slight immunosuppression" continue for several days or weeks beyond delivery so that there might be a concern should the mother require blood products just after delivery as well as during pregnancy?
Submit comments to the e-Network Forum at email@example.com
Ira A. Shulman, MD
CBBS e-Network Forum Senior Editor & Moderator
W. Tait Stevens, MD
CBBS e-Network Forum Editor & Moderator
Elizabeth M. St. Lezin, MD
CBBS e-Network Forum Associate Editor & Moderator
The e-Network Forum is supported in part by the California Blood Bank Society (CBBS) and the American Red Cross Blood Services (ARCBS) and endorses collegial discussion among blood banking and transfusion medicine professionals. However, neither the CBBS nor the ARCBS in any way endorse the specific views and opinions expressed in the forum. The forum is not intended as a substitute for medical or legal advice and the content should not be relied upon for any medical or legal purposes. Readers should make their own determinations as to: (i) what constitutes appropriate medical, technical, and administrative practices, and (ii) how best to comply with laws and regulations relevant to their questions. For the latter, they should consider consulting, as to any medical matters, a qualified physician, and, as to any legal matters, an attorney familiar with related state and federal laws. The user of the forum, by accessing same, assumes all risks arising out of such use and releases CBBS and their respective members, directors, officers and agents from and against any loss, damage, claim or liability arising out of such use of the Forum.